Pinned Tweet
Biotech, explained by the science. Gene editing, clinical readouts, M&A, AI and robotics firsts, longevity and psychedelic medicines. Hard numbers, honest caveats. 🧬
173
Depression scores split from placebo by Day 2, and the gap held to Week 12.
$HELP HLP003 (deuterated psilocin) on top of an antidepressant, Phase 3, 222 patients: MADRS 7.6 points better at Week 6, remission 50.9% vs 18.2%.
Second pivotal reads 4Q 2027. Will it replicate?
3
4
218
Source: Helus Pharma topline PR globenewswire.com/news-relea…
48
3 of 4 evaluable patients gained retinal sensitivity on the low dose of a retinal gene therapy.
$IRD OPGx-BEST1, BIRD-1 cohort 1: structural gains in 4 of 5, no SAEs. High dose (11 dosed) reads out Q1 2027.
Open label, 5 patients. Does dose widen it?
1
75
Source: Opus Genetics Q3 update, Nov 10
ir.opusgtx.com/press-release…
25
Median survival 24.0 vs 14.7 months from a peptide vaccine in relapsed AML.
$SLS galinpepimut-S, Phase 3 REGAL (126 patients, second remission, no transplant): HR 0.59, p=0.035 at 80 deaths. Mostly mild injection site reactions.
Open label, thin p. Do the secondaries hold?
Source: SELLAS press release (Nov 17), also filed as an 8-K. BLA planned 1H 2027 after an FDA meeting.
ir.sellaslifesciences.com/ne…
Weight lost on semaglutide alone was 68% fat, 32% lean. With enobosarm 3 mg added, it was 100% fat.
$VERU QUALITY post hoc, age 65+ (n=29 vs 30), 16 weeks: stair climb power +16.5% and climb time −16.3%, placebo corrected.
Caveat: post hoc subset. Does PLATEAU confirm it?
1
120
Source: planion.events/e/tos/ow2026/… (Oral-115, podium Mon Nov 16 5:15 PM ET).
39
5.0% weight loss at 12 wks from a CB1 inverse agonist built to stay out of the brain.
$CRBP CRB-913, CANYON-1 (n=254, 20/40/60 mg): irritability 6.2/8.2/9.7% vs 0%, anxiety 3.1/8.2/4.8% vs 4.5%, depression 0/0/1.6% vs 0% placebo.
Caveat: 12 wks. Did peripheral restriction hold?
1
1
335
Source: Corbus CANYON-1 topline press release (psychiatric TEAE table), poster at ObesityWeek 2026: ir.corbuspharma.com/news-eve…
52
14.3% less visceral fat from one shot, while lean mass rose 2.4%.
$WVE WVE-007 (GalNAc siRNA silencing INHBE), Phase 1 INLIGHT interim at ObesityWeek: single 240 mg dose, placebo adjusted, month 6 DEXA. 🧵
1
466
80% mean drop in non-sustained VT in the 7 high-dose patients.
$LXEO LX2020, an AAV gene therapy restoring PKP2 in arrhythmogenic cardiomyopathy, Phase I/II: PVC burden down 44%. FDA is open to NSVT as a pivotal surrogate.
Open label and small. Will it hold up?
$LXEO announces positive interim data from the HEROIC-PKP2 Phase I/II trial of LX2020 for the treatment of PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM)
finance.yahoo.com/healthcare…
Aficamten beat metoprolol head to head: peak VO2 +1.1 vs −1.2 mL/kg/min at 24 weeks (difference 2.3, p<0.001, 175 patients).
$CYTK MYQORZO label now includes MAPLE-HCM. Indication unchanged; boxed heart failure warning and REMS stay.
Enough to move it ahead of beta blockers?
$CYTK FDA Approves sNDA to Update Prescribing Information for MYQORZO (aficamten) to Include Data from Phase 3 MAPLE-HCM
1
356
Source: Cytokinetics PR, Nov 16 (label update) ir.cytokinetics.com/press-re…
Trial data: NEJM MAPLE-HCM nejm.org/doi/full/10.1056/NE…
72
At least 90% of patients were attack free in every month for up to four years after one CRISPR infusion.
$NTLA lonvo-z 50 mg Phase 1/2 HAE follow up at ACAAI: 32 patients, 100% off long term prophylaxis. Phase 3 HAELO cut monthly attacks 87% vs placebo. PDUFA by Mar 10 2027.
Small open label cohort.
2
10
1,099
Source: Intellia ACAAI 2026 release globenewswire.com/news-relea…
111



